eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
2/2017
vol. 9
 
Share:
Share:
more
 
 
abstract:
Original paper

High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience

Rajendra Bhalavat, Manish Chandra, Vibhay Pareek, Lalitha Nellore, Karishma George, Nandakumar P., Pratibha Bauskar

J Contemp Brachytherapy 2017; 9, 2: 124–131
Online publish date: 2017/04/13
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose: To evaluate the treatment outcomes with high-dose-rate (HDR) interstitial brachytherapy (HDR-BRT) in head and neck cancers (HNC).

Material and methods: Fifty-eight patients with HNC as per American Joint Committee on Cancer (AJCC) TNM staging criteria were analyzed retrospectively between 2008 and 2015. Forty-two patients received external beam radiotherapy (EBRT) with HDR-BRT and 16 patients received BRT alone. The survival was calculated with respect to median biological equivalent doses (BED) and median 2 Gy equivalent dose (EQD2), keeping / = 10 for tumor. Loco-regional control and disease free survival was assessed.

Results: The median follow-up period was 25 months (2-84 months). The disease-free survival (DFS) probability at year 1 was 82.7%, and 68% at year 7. The overall survival probability was 91.3% at year 1 and 85.8% at year 7. The local control rate was 70%. The rate of recurrence was 30%. Distant metastasis rate was 17.2%. The median BED and EQD2, respectively, were 86.78 Gy and 71.6 Gy. The DFS was 74.1% and 75.9% in patients receiving a dose more than median BED and EQD2, respectively, and was 64.8% and 61.5% for less than the median dose.

Conclusions: The overall outcome was good with implementation of HDR-BRT used alone or as boost, and shows DFS as better when the dose received is more than the median BED and median EQD2. The role of HDR-BRT in HNC is a proven, effective, and safe treatment method with excellent long term outcome as seen in this study, which reflects the need for reviving the forgotten art and science of interstitial brachytherapy in HNC.
keywords:

BED, EQD2, HDR, head and neck cancer, interstitial brachytherapy

references:
Sankaranarayan R, Masuyer E, Swaminathan R et al. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 1998; 18: 4779-4786.
Sanghvi LD, Rao DN, Joshi S. Epidemiology of head and neck cancer. Semin Surg Oncol 1989; 5: 305-309.
Takiar R, Nadayil D, Nandakumar A. Projections of number of cancer cases in India (2010-2020) by cancer groups. Asian Pac J Cancer Prev 2010; 11: 1045-1049.
Indian Council of Medical Research (ICMR). An Atlas for Cancer in India, 2002.
Paine CH, Ash DV. Interstitial brachytherapy: past, present, future. Int J Radiat Oncol Biol Phys 1991; 21: 1479-1483.
Erickson BA, Demanes DJ, Ibbott GS et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79: 641-649.
Mazeron JJ, Ardiet JM, Haie-Méder C et al. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009; 91: 150-156.
Guedea F, Venselaar J, Hoskin P et al. Patterns of care for bra­chytherapy in Europe: updated results. Radiother Oncol 2010; 97: 514-520.
Petera J, Matula P, Paluska P et al. High dose rate versus low dose rate brachytherapy in the treatment of tongue carcinoma – a radiobiological study. Neoplasma 2009; 56: 163-168.
Nag S, Cano ER, Demanes DJ et al. The American Brachy­therapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2001; 50: 1190-1198.
Bhalavat RL, Laskar S, Saple MP et al. Technique for interstitial brachytherapy of carcinoma of the tongue. J Brachytherapy Int 1998; 14: 179-183.
Bartochowska A, Wierzbicka M, Skowronek J et al. High-dose- rate and pulsed-dose-rate brachytherapy in palliative treatment of head and neck cancers. Brachytherapy 2012; 11: 137-143.
Kovács G. Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy. J Contemp Brachytherapy 2015; 6: 404-416.
Pierquin B, Wilson JF, Chassagne D et al. Brachytherapy in base of tongue. In: Modern brachytherapy. Pierquin B, Wilson JF, Chassagne D (eds.). Masson Publishing Inc., New York 1987; p. 147.
Jones B, Dale RG, Deehan C et al. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol 2001; 13: 71-81.
List MA, Bilir SP. Evaluations of quality of life and organ function. Semin Oncol 2004; 31: 827-835.
ICRU, International Commission of Radiation Units and Measurements. Dose and volume specification for reporting interstitial therapy. ICRU report 58. Bethesda, 1997.
Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972; 29: 1446-1449.
Choi WH, Hu KS, Culliney B et al. Cancer of the oropharynx. In: Head and Neck Cancer: A Multidisciplinary Approach. Harrison LB, Sessions RB, Hong WK (eds.). 3rd ed. Lippincott, William & Wilkins, Philadelphia 2009; p. 285-335.
Yamazaki H, Yoshida K, Yoshioka Y et al. High dose rate brachytherapy for oral cancer. J Radiat Res 2013; 54: 1-17.
Guinot JL, Santos M, Tortajada MI et al. Efficacy of high-dose-rate interstitial brachytherapy in patients with oral tongue carcinoma. Brachytherapy 2010; 9: 227-234.
Nose T, Koizumi M, Nishiyama K. High-dose-rate interstitial brachytherapy for oropharyngeal carcinoma: results of 83 lesions in 82 patients. Int J Radiat Oncol Biol Phys 2004; 59: 983-991.
Mohanti BK, Bansal M, Bahadur S et al. Interstitial bra­chytherapy with or without external beam irradiation in head and neck cancer: Institute Rotary Cancer Hospital experience. Clin Oncol (R Coll Radiol) 2001; 13: 345-352.
Ghadjar P, Bojaxhiu B, Simcock M et al. High dose-rate versus low dose-rate brachytherapy for lip cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1205-1212.
Glatzel M, Büntzel J, Schröder D et al. High-dose-rate bra­chytherapy in the treatment of recurrent and residual head and neck cancer. Laryngoscope 2002; 112: 1366-1371.
Gibbs IC, Le QT, Shah RD et al. Long-term outcomes after external beam irradiation and brachytherapy boost for base-of-tongue cancers. Int J Radiat Oncol Biol Phys 2003; 57: 489-494.
 
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe